Eton Pharmaceuticals (ETON) Raw Materials (2024 - 2025)
Eton Pharmaceuticals (ETON) reported Raw Materials of $557000.0 for Q4 2025, down 89.6% on a YoY basis from $5.4 million in Q4 2024, and down 89.6% sequentially from $5.4 million in Q4 2024.
Eton Pharmaceuticals (ETON) Raw Materials (2024 - 2025) Analysis & Trends
Eton Pharmaceuticals (ETON) has 2 years of Raw Materials data on file, last reported at $557000.0 in Q4 2025.
- For the quarter ending Q4 2025, Raw Materials fell 89.6% year-over-year to $557000.0; the trailing twelve-month figure through Dec 2025 stood at $557000.0 (down 89.6% YoY), and the FY2025 full-year result was $557000.0, down 89.6% from the prior year.
- Raw Materials fell to $557000.0 in Q4 2025, from $5.4 million in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $5.4 million in Q4 2024 to a low of $557000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Eton Pharmaceuticals | 1.19 Bn | 1.16 Bn | 13.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 557,000.00 |
| Dec 31, 2024 | 5.36 Mn |